Supplementary Figure 1: Effects of the NAMPT inhibitor FK866 and KYN supplementation.
From: Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation
HuMDMs were treated with either vehicle or FK866 (10 μM, 20 h) and were supplemented with either vehicle or KYN (25 μM, 20 h). a, Representative western blot of NAD+ synthetic enzymes NMNAT1 and NADS and NAMPT; n = 3 per group, shown as mean ± S.E. with protein levels normalized to β-actin; non-significance determined by Student’s two-tailed t test. b, Administration of NMN to FK866-treated huMDMs restores NAD+ levels, as measured by LC/MS; n = 6 per group, represented as mean ± S.E., two-way ANOVA: effects of NMN and FK866, P < 0.0001 with Tukey post hoc test: ****P < 0.0001. c, LC/MS measurements of QA, NaMN, NaAD; n = 6 per group, represented as mean ± S.E.; two-way ANOVA, for QA effect of KYN, P < 0.0001; for NaMN, effects of KYN and FK866, P < 0.0001; for NaAD, effects of KYN and FK866, P < 0.001; Tukey post hoc tests: ***P = 0.0001 QA: veh-veh versus KYN-veh; ***P = 0.0002 QA: veh-FK866 versus KYB-FK866; ****P < 0.0001 NaMN: veh-veh versus KYN-veh; ####P < 0.0001 KYN-veh versus KYN-FK866; ***P = 0.0002 NaAD: veh-veh versus KYN-veh; ###P = 0.0002 NaAD: KYN-veh versus KYN-FK866. d, Reaction mechanism for isotope labeling of KYN to generate M+2 de novo NAD+.
